PopsiCube, a global clinical research organization (CRO) with branches in France, the US, and China, has opened an additional affiliate in Russia to provide full clinical trial services in the region.
PopsiCube’s Russian affiliate, PopsiCube Rus ooo, is strategically based in Moscow near academic and research institutions located in the region. The affiliate company will enable PopsiCube’s international growth objectives through a Russian client base, according to the CRO
CEO of PopsiCube Fabrice Beauchêne told us that Russia was chosen as the company’s next affiliate for a multitude of reasons. “Despite major economic challenges, Russia has a large pharmaceutical market offering various opportunities to market players,” he said, adding that the pharmaceutical sector is also a priority for the Russian government.
Additionally, Beauchêne said that the professional team leading the Russian affiliate is comprised of three women with experiences at PPD and AstraZeneca.
The opportunity for clinical trials in treatment-naïve patients is also a benefit of adding a Russian affiliate, according to Beauchene. In Russia, roughly 800-1000 clinical trials are initiated per year, but Russia is the largest country in the world with a strong representation of different ethnicities which can be beneficial in clinical trials.
Beauchêne also told us that beyond this agreement with Russia, PopsiCube expects to sign an agreement with an early phase unit in Kazakhstan.